Protara Therapeutics (NASDAQ:TARA) Announces Earnings Results

Protara Therapeutics (NASDAQ:TARA) announced its quarterly earnings data on Wednesday. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.09, Zacks reports.

Protara Therapeutics Stock Up 2.2 %

Shares of NASDAQ:TARA traded up $0.08 during midday trading on Wednesday, reaching $3.44. 11,065 shares of the company were exchanged, compared to its average volume of 311,473. Protara Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $10.48. The stock has a fifty day simple moving average of $4.66 and a two-hundred day simple moving average of $3.39. The firm has a market cap of $70.86 million, a PE ratio of -1.23 and a beta of 1.63.

Analysts Set New Price Targets

TARA has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $23.00 price target on shares of Protara Therapeutics in a research report on Friday, December 6th. Guggenheim restated a “buy” rating and set a $20.00 price objective on shares of Protara Therapeutics in a report on Friday, December 6th.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.